Mark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.
Mark Pegram, MD, Susy Yuan-Huey Hung professor of Oncology, medical director, Clinical and Translational Research Unit, associate dean, Clinical Research Quality, Stanford University School of Medicine, discusses the evolving treatment landscape of HER2-positive breast cancer.
The emergence of new agents and data in the HER2-positive breast cancer space in recent years has been practice changing, Pegram explains. However, this barrage of information has created a challenge for practitioners to keep up with the fast pace of change, given all of the new drugs and their varying toxicity profiles, despite all of the excitement generated by emerging therapies, Pegram says.
Even with the rapid pace of change in recent years, more agents and data are expected to emerge in the coming years, Pegram continues. There has never been a more exciting time to be involved in clinical research in HER2-positive breast cancer, and that will not change anytime soon, Pegram concludes.